Aldehyde dehydrogenase 1 expression is correlated with poor prognosis in breast cancer

Medicine (United States)

Volumn 96, Issue 25, 2017, Pages

  Yao, Juan ^a,b   Jin, Qin ^a   Wang, Xu Dong ^a   Zhu, Hui Jun ^a   Ni, Qi Chao ^a   Fan, Huitao ^c  

^a NANTONG UNIVERSITY   (China)

^b Huaiyin Hospital of Huaian City   (China)

^c NONE

Author keywords

ALDH1; Breast cancer; Clinicopathological factors; Immunohistochemistry; Prognosis; QRT PCR

Indexed keywords

ALDEHYDE DEHYDROGENASE ISOENZYME 1; MESSENGER RNA; PARAFFIN; ALDEHYDE DEHYDROGENASE; ALDH1A1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; BREAST CANCER; BREAST CELL; CANCER GRADING; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LOG RANK TEST; MAJOR CLINICAL STUDY; MOLECULAR TYPING; OVERALL SURVIVAL; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RADICAL MASTECTOMY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL TIME; TISSUE MICROARRAY; TRIPLE NEGATIVE BREAST CANCER; BREAST; BREAST TUMOR; ENZYMOLOGY; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; PATHOLOGY; PROGNOSIS; SOFTWARE; TUMOR VOLUME;

ALDEHYDE DEHYDROGENASE; BIOMARKERS, TUMOR; BREAST; BREAST NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; NEOPLASM METASTASIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SOFTWARE; TISSUE ARRAY ANALYSIS; TUMOR BURDEN;

EID: 85021748999     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000007171     Document Type: Article

References (35)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016; 66: 7-30
2. ChenW, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin 2016; 66: 115-32
3. Lv X, Wang Y, Song Y, et al. Association between ALDH1+/CD133+ stem-like cells and tumor angiogenesis in invasive ductal breast carcinoma. Oncol Lett 2016; 11: 1750-6
4. Martin M, Hinojar A, Cerezo L, et al. Aldehyde dehydrogenase isoform 1 (ALDH1) expression as a predictor of radiosensitivity in laryngeal cancer. Clin Transl Oncol 2016; 18: 825-30
5. Kim SJ, Kim YS, Jang ED, et al. Prognostic impact and clinicopathological correlation of CD133 and ALDH1 expression in invasive breast cancer. J Breast Cancer 2015; 18: 347-55
6. Barr MP, MacDonagh L, Gray SG, et al. 75P Inhibition and exploitation of aldehyde dehydrogenase 1 (ALDH1) as a cancer stem cell marker in cisplatin resistant NSCLC. J Thorac Oncol 2016; 11(4 suppl): S87
7. Zhao Y, Jin X, Li N, et al. [Expression and Clinical Significance of ALDH1 and Twist in Gastric Adenocarcinoma]. Sichuan Da Xue Xue Bao Yi Xue Ban 2016; 47: 54-9
8. Ma YM, Zhao S. Prognostic values of aldehyde dehydrogenase 1 isoenzymes in ovarian cancer. Onco Targets Ther 2016; 9: 1981-8
9. Tomita H, Tanaka K, Tanaka T, et al. Aldehyde dehydrogenase 1A1 in stem cells and cancer. Oncotarget 2016; 7: 11018-32
10. Mansour SF, Atwa MM. Clinicopathological significance of CD133 and ALDH1 cancer stem cell marker expression in invasive ductal breast carcinoma. Asian Pac J Cancer Prev 2015; 16: 7491-6
11. Kunju LP, Cookingham C, Toy KA, et al. EZH2 and ALDH-1 mark breast epithelium at risk for breast cancer development. Mod Pathol 2011; 24: 786-93
12. Kida K, Ishikawa T, Yamada A, et al. Effect of ALDH1 on prognosis and chemoresistance by breast cancer subtype. Breast Cancer Res Treat 2016; 156: 261-9
13. Yoshioka T, Umekita Y, Ohi Y, et al. Aldehyde dehydrogenase 1 expression is a predictor of poor prognosis in node-positive breast cancers: A long-Term follow-up study. Histopathology 2011; 58: 608-16
14. Pan H, Wu N, Huang Y, et al. Aldehyde dehydrogenase 1 expression correlates with the invasion of breast cancer. Diagn Pathol 2015; 10: 66
15. Ginestier C, Hur MH, Charafe-Jauffret E, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007; 1: 555-67
16. Dong Y, Bi LR, Xu N, et al. The expression of aldehyde dehydrogenase 1 in invasive primary breast tumors and axillary lymph node metastases is associated with poor clinical prognosis. Pathol Res Pract 2013; 209: 555-61
17. Currie MJ, Beardsley BE, Harris GC, et al. Immunohistochemical analysis of cancer stem cell markers in invasive breast carcinoma and associated ductal carcinoma in situ: Relationships with markers of tumor hypoxia and microvascularity. Hum Pathol 2013; 44: 402-11
18. Collina F, Di Bonito M, Li Bergolis V, et al. Prognostic value of cancer stem cells markers in triple-negative breast cancer. Biomed Res Int 2015; 2015: 158682
19. Seo AN, Lee HJ, Kim EJ, et al. Expression of breast cancer stem cell markers as predictors of prognosis and response to trastuzumab in HER2-positive breast cancer. Br J Cancer 2016; 114: 1109-16
20. Liu Y, Baglia M, Zheng Y, et al. ALDH1A1 mRNA expression in association with prognosis of triple-negative breast cancer. Oncotarget 2015; 6: 41360-9
21. Frierson HFJr, Wolber RA, Berean KW, et al. Interobserver reproducibility of the Nottingham modification of the Bloom and Richardson histologic grading scheme for infiltrating ductal carcinoma. Am J Clin Pathol 1995; 103: 195-8
22. Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: Highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 2013; 24: 2206-23
23. Wang Q, Ni Q, Wang X, et al. High expression of RAB27A and TP53 in pancreatic cancer predicts poor survival. Med Oncol 2015; 32: 372
24. Li J, Huang J, Huang F, et al. Decreased expression of IDH1-R132H correlates with poor survival in gastrointestinal cancer. Oncotarget 2016; 7: 73638-50
25. Lawson DA, Bhakta NR, Kessenbrock K, et al. Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells. Nature 2015; 526: 131-5
26. Zhong Y, Shen S, Zhou Y, et al. ALDH1 is a better clinical indicator for relapse of invasive ductal breast cancer than the CD44+/CD24-phenotype. Med Oncol 2014; 31: 864
27. Doherty MR, Smigiel JM, Junk DJ, et al. Cancer stem cell plasticity drives therapeutic resistance. Cancers 2016; 8: 8
28. Miyoshi Y, Shien T, Ogiya A, et al. Differences in expression of the cancer stem cell marker aldehyde dehydrogenase 1 among estrogen receptor-positive/human epidermal growth factor receptor type 2-negative breast cancer cases with early, late, and no recurrence. Breast Cancer Res 2016; 18: 73
29. Li H, Ma F, Wang H, et al. Stem cell marker aldehyde dehydrogenase 1 (ALDH1)-expressing cells are enriched in triple-negative breast cancer. Int J Biol Markers 2013; 28: E357-64
30. Ricardo S, Vieira AF, Gerhard R, et al. Breast cancer stem cell markers CD44, CD24 and ALDH1: Expression distribution within intrinsic molecular subtype. J Clin Pathol 2011; 64: 937-46
31. Chen J, Xia Q, Jiang B, et al. Prognostic value of cancer stem cell marker ALDH1 expression in colorectal cancer: A systematic review and metaanalysis. PLoS ONE 2015; 10: E0145164
32. Lee HE, Kim JH, Kim YJ, et al. An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer. Br J Cancer 2011; 104: 1730-8
33. Park SY, Lee HE, Li H, et al. Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer. Clin Cancer Res 2010; 16: 876-87
34. Takebe N, Warren RQ, Ivy SP. Breast cancer growth and metastasis: Interplay between cancer stem cells, embryonic signaling pathways and epithelial-To-mesenchymal transition. Breast Cancer Res 2011; 13: 211
35. Zhao D, Mo Y, Li MT, et al. NOTCH-induced aldehyde dehydrogenase 1A1 deacetylation promotes breast cancer stem cells. J Clin Invest 2014; 124: 5453-65